WO2002018448A2 - Percarboxylated polysaccharides, and a process for their preparation - Google Patents
Percarboxylated polysaccharides, and a process for their preparation Download PDFInfo
- Publication number
- WO2002018448A2 WO2002018448A2 PCT/EP2001/010062 EP0110062W WO0218448A2 WO 2002018448 A2 WO2002018448 A2 WO 2002018448A2 EP 0110062 W EP0110062 W EP 0110062W WO 0218448 A2 WO0218448 A2 WO 0218448A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- percarboxylated
- acid
- hyaluronic acid
- biomaterial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
- C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Definitions
- the present invention describes percarboxylated polysaccharides, the process for their preparation and their use in the pharmaceutical field and in the preparation of biomaterials for surgical, biomedical and healthcare uses. State of the art
- Hyaluronic acid is a heteropolysaccharide composed of alternating residues of D- glucuronic acid and N-acetylglucosamine. It is a polymer with a linear chain and a molecular weight that may vary between 50,000 and 13,000,000 Da, according to the source from which it is obtained and the methods used to prepare it. It is present in nature in the pericellular gels, in the fundamental substance of the connective tissue of vertebrate organisms, of which it represents one of the main components, in the synovial fluid of joints, in the vitreous humor, in the tissues of human umbilical cords and in cockscombs.
- the present invention relates to "percarboxylated" hyaluronic acid derivatives, comprising at least one repeating unit of formula (I):
- R is OH, O " , an alcoholic or an amino group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic and heterocyclic series;
- Ri is COR ⁇ , wherein R 6 is OH, O " , an alcoholic or an amino group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic and heterocyclic series; an alcoholic group of hyaluronic acid, or an amino group of N-deacetylated hyaluronic acid;
- R 2 , R 3 , 4 . equal or different from each other, are H, SO 3 " , an acyl group deriving from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series; or a residue of hemiester of succinic acid or of heavy metal salts of hemiester of succinic acid;
- percarboxylated polysaccharides selected from the group consisting of gellan, carboxymethylcellulose, pectin and pectic acid.
- the present invention also relates to the process for their preparation and the numerous applications of such products in the pharmaceutical, biomedical, surgical and healthcare fields.
- percarboxylated means that all or part of the primary hydroxyl groups present on the polymer have been replaced by carboxy groups, and modifications thereof, by an oxidation process.
- percarboxylation degree means the percentage of carboxy groups, or modifications thereof, introduced by an oxidation process. According to the invention, the percarboxylation degree of the present derivatives is comprised between 1% and 100%, and preferably between 25% and 75%.
- the present invention relates to new "percarboxylated" polysaccharides selected from the hyaluronic acid derivatives of formula (I) above reported, gellan, carboxymethylcellulose, pectin and pectic acid.
- percarboxylated derivatives of hyaluronic acid according to the present invention the following are to be preferred:
- ACP autocross-linked hyaluronic acid
- aliphatic means acyclic or pertaining to open-chain or branched carbon compounds such as alkanes, alkenes or alkynes.
- Examples of an aliphatic moiety include but are not limited to C1-C20 noncyclic hydrocarbons and their isomers such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 2-methylbutyl, 1 ,2-dimethylpropyl, hexyl, isohexyl, 1- methylpentyl, 2-methylpentyl, 3-methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyI, 2,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1 ,
- aromatic means an aryl moiety having one or more unsaturated rings, each ring usually having 5 to 8 members and preferably 5 to 6 members.
- aromatic moiety include but are not limited to benzyl, toluyl, naphalyl, anthracenyl, phenantryl, fluorenyl, coronenyl, triphenylenyl, fluoranthenyl, benzofluoranthenyl, benzopyrenyl and pyrenyl.
- cycloaliphatic indicates a carbon ring structure, usually having 3 to 8 members and preferably 5 to 6 members, that does not contain a resonance structure.
- cycloaliphatic groups include but are not limited to cycloalkanes and cycloolefins such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexenyl (tetrahydrobenzenyl), cyclohexylidenyl, and cyclooctadienyl.
- cycloalkanes such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexenyl (tetrahydrobenzenyl), cyclohexylidenyl, and cyclooctadienyl.
- heterocyclic relates to dissimilar atoms in a ring.
- a heterocyclic group is a heteroaryl group usually having a 3- to 8-membered, preferably 5- to 6-membered ring or fused ring containing at least one hetero atom (such as O, S, N, etc.) and include but are not limited to thienyl, furanyl, pyranyl, 2H-pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, isothiazolyl, isoxazolyl, furazanyl, benzothienyl, isobenzofuranyl, chromenyl, indolindinyl, isoindolyl, indolyl, purinyl, quinolidinyl, isoquinolyl, quinolyl, phtalazinyl, quinazolyl, carbazo
- arylaliphatic means a group having both aromatic and aliphatic substituents as defined above.
- arylalkyl groups include but are not limited to ethylbenzenyl, isobutylbenzeneyl, benzyl, ethylbenzyl, propylbenzyl, isopropylbenzyl, butylbenzyl, isobutylbenzyl, cyclohexylbenzyl, styrenyl, and biphenyl.
- Percarboxylated hyaluronic acid derivatives can be used for the preparation of pharmaceutical compositions, for example in the form of gels, for the transport and release of drugs and biologically active substances to be used in viscoelastic surgery or ophthalmic surgery.
- the present percarboxylated derivatives can also by salified with heavy metals wherein the heavy metals are the elements of the 4 th , 5 th or 6 th period of the periodic table, such as silver, iron, cobalt, copper, zinc, arsenic, strontium, zirconium, antimony, gold, cesium, tungsten, selenium and platinum, ruthenium, bismuth, tin, titanium, gallium, mercury.
- salts can be used in dermatology, ophthalmology, dentistry, rheumatology, urology, gynaecology, internal surgery, as food supplements, antioxidants, antirheumatic and anticancer agents, antiinflammatories, analgesics and antiulcer agents.
- the salts of the present percarboxylated derivatives may be prepared with pharmacologically and/or biologically active substances.
- antibiotics antibiotics, anti-infective, antimicrobial, antifungal, antiviral, cytostatic, cytotoxic, anticancer, anti-inflammatory, wound-healing agents, anaesthetics, analgesics, vasoconstrictors, cholinergic or adrenergic agonists and antagonists, antithrombotics, anticoagulants, haemostatic, fibrinolytic, thrombolytic agents.
- biologically active substances should be intended for example proteins and their fragments, peptides, polynucleotides, growth factors, enzymes, vaccines, or substances used in the treatment of diseases associated with genetic defects, such as those that are caused by enzymatic hypo- or hyperactivity due to defects of the gene that codes for a given enzyme, or deforming or hereditary diseases.
- the present percarboxylated derivatives can also be used in association with radioactive and non-radioactive substances used in contrast systems, and as tracers in in vivo diagnostics for the identification and cure of cancer tissues or damaged tissues.
- a considerable advantage is represented by the possibility of processing the compounds of the present invention and their salts in various forms of biomaterials such as sponges, films, membranes, threads, tampons, non-woven tissues, felts, microspheres, nanospheres, gauze pads, gels, guide channels, and associations thereof.
- biomaterials such as sponges, films, membranes, threads, tampons, non-woven tissues, felts, microspheres, nanospheres, gauze pads, gels, guide channels, and associations thereof.
- biomaterials may be constituted by one or more of the present percarboxylated derivatives, optionally in association with natural, synthetic, semisynthetic polymers and, optionally, further being in combination with pharmacologically and/or biologically active substances.
- Examples of the natural polymers that can be used are collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin and pectic acid, agar, agarose, xanthane, gellan, alginic acid or the alginates, polymannan or polyglycans, starch, natural gums.
- Examples of semisynthetic polymers of possible use are collagen cross-linked with agents such as aldehydes or precursors of the same, dicarboxylic acids or their halides, diamine, derivatives of cellulose, hyaluronic acid, chitin or chitosan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gums and glycosaminoglycans.
- agents such as aldehydes or precursors of the same, dicarboxylic acids or their halides, diamine, derivatives of cellulose, hyaluronic acid, chitin or chitosan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gums and glycosaminoglycans.
- Synthetic polymer can be chosen, for example, from the group consisting of polylactic acid, polyglycolic acid or the derivatives thereof, polydioxanes, polyphosphazenes, polysulphonic resins, polyurethanes, PTFE.
- biomaterials can be used in various surgical fields, for example in internal surgery, osteo-articular surgery, neurosurgery, anastomotic, viscoelastic, ophthalmic, oncological, plastic-aesthetic, otolaryngological, abdominal-pelvic, urogynaecological, cardiovascular surgery, in the prevention of post-surgical adhesions and hypertrophic scars.
- biomaterials in their various forms, are particularly suitable for use as scaffolds for the growth of cells such as mesenchymal or mature cells to obtain connective, bone, glandular, nervous, muscular, hepatic tissue etc.
- the biomaterials comprising the present percarboxylated derivatives can be used, in association with biologically and/or pharmacologically active substances, as vehicling agents for the preparation of slow release pharmaceutical compositions; moreover, the present percarboxylated derivatives can be used as the active ingredients, in combination with pharmaceutically acceptable excipients and/or diluents, for the preparation of pharmaceutical compositions.
- the derivatives thus obtained can also be used in the processes of coating objects used both in the medical field and in other sectors of industry, providing new biological characteristics to the surfaces of the materials used as supports.
- the objects that can be thus coated are, for example, catheters, guide channels, probes, cardiac valves, soft tissue replacements, replacements of animal origin, artificial tendons, bone and cardiovascular replacements, contact lenses, blood oxygenators, artificial kidneys, hearts, pancreas and livers, blood bags, syringes, surgical instruments, filtration systems, laboratory instruments, containers for cell and tissue culture and regeneration, supports for peptides, proteins and antibodies.
- the process of coating the surfaces of such objects can be performed by the Plasma Coating technique, as described in the international patent application by the Applicant, No. WO96/24392.
- the present percarboxylated derivatives can be obtained by an oxidation process, that acts selectively on the primary hydroxyl groups, for example by reaction of the polisaccharide, selected from hyaluronic acid and derivatives thereof, gellan, carboxymethylcellulose, pectic acid and pectin, with sodium hypochlorite in aqueous solution at a low temperature, preferably ranging between 0°C and -1 °C, and in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO).
- the degree of percarboxylation deriving therefrom depends on the quantity of the oxidising agent (hypochlorite) used in the reaction.
- the starting polysaccharide is a hyaluronic acid derivative
- the present process has lead to the desired percarboxylated products, without showing the drawbacks expected, and in particular the substantial degradation of the polymer disclosed by Bo Jiang et al.
- the process for the preparation of percarboxylated hyaluronic acid derivatives wherein Re is different from OH or O " comprises the following steps: a) selective oxidation of part or all primary hydroxyl groups of the starting hyaluronic acid derivatives; b) preparation of the quaternary ammonium salt, preferably the tetrabutylammonium salt, of the percarboxylated hyaluronic acid derivative coming from step a); c) reaction of the said quaternary ammonium salt coming from step b) with different reagents depending on which is the derivative desired.
- the quaternary ammonium salt is reacted with a sulphating agent to obtain the O- sulphated or N-suIphated derivatives, with chloromethylpyridinium iodide to obtain the autocross-linked derivatives, with succinic anhydride to obtain the hemiesters of succinic acid, etc., as disclosed in the above patent documents, herewith incorporated by reference.
- the product thus obtained is characterised analytically to determine the percentage of carboxylation.
- the solution is neutralised to pH 6 and precipitated with acetone.
- the solution is neutralised to pH 6 and precipitated with acetone.
- the product thus obtained is characterised analytically to determine the percentage of carboxylation.
- a precipitate is formed that is filtered and washed three times in 100 ml of acetone/water (ratio 5:1), three times in 100 ml of acetone, and then vacuum-dried for 24 hours at 30°C.
- 4.25 g of the desired product are obtained with 125% of total benzylic esterification (it should be intended that all the carboxy groups of the polymer not percarboxylated, and all the carboxy groups coming from percarboxylation are esterified).
- Quantitative determination of the benzylic alcohol content is conducted by gas chromatography after alkaline hydrolysis.
- ester groups The total content of ester groups is determined according to the saponification method described on pages 169-172 of "Quantitative organic analysis via functional groups', IV Ed., John Wiley and Sons Publication.
- EXAMPLE 6 Preparation of cross-linked hyaluronic acid (ACP) from hyaluronic acid with 50% percarboxylation
- tetrabutylammonium salt of percarboxylated hyaluronic acid according to example 2 is solubilised in 260 ml of N-methyl-2-pirrolidone (NMP) at room temperature.
- NMP N-methyl-2-pirrolidone
- To this solution is added 1.4 ml of triethylamine (10 mmoles) and the resulting solution is agitated for 30 minutes.
- To this solution is added 0.766 mg of 2-chloro-1-methyl-pyridinium iodide equal to 30% of the initial moles of percarboxylated hyaluronic acid dissolved in 5 ml of NMP. The solution is agitated for 4 hours at room temperature.
- dialysed solution does not become cloudy on contact with the silver nitrate solution, this indicates that no chloride residues are present.
- the salt-free, dialysed solution is freeze-dried and analysed for its zinc content.
- the zinc content proves to be 10% bivalent zinc (Zn 2+ ), vs the theoretical content of 7.95.
- the resulting percentage perfectly reflects the value of percarboxylation of the hyaluronic acid used.
- EXAMPLE 8 Preparation of films using percarboxylated hyaluronic acid esters (HYAFF®)
- a solution equal to 100 mg/ml of the percarboxylated derivative in dimethylsulphoxide (DMSO) according to Example 5 is prepared by dissolving 1 g of benzyl ester at 125% in 10 ml of DMSO.
- a thin layer of solution is spread over a glass plate, taking care to create a layer that is 10 times thicker than the desired thickness of the final film.
- the glass plate is immersed in a bath of ethanol that absorbs the DMSO but does not solubilise the percarboxylated hyaluronic acid ester, which solidifies.
- the film is detached from the glass plate and washed repeatedly with water and again with ethanol.
- the film thus obtained is dried in a press for 24 hours at 30°C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002523962A JP2004507586A (en) | 2000-08-31 | 2001-08-31 | Percarboxylic esterified polysaccharides and methods for producing them |
CA2420618A CA2420618C (en) | 2000-08-31 | 2001-08-31 | Percarboxylated polysaccharides, and a process for their preparation |
EP01971988A EP1339753A2 (en) | 2000-08-31 | 2001-08-31 | Percarboxylated polysaccharides, and a process for their preparation |
AU9181501A AU9181501A (en) | 2000-08-31 | 2001-08-31 | Percarboxylated polysaccharides, and a process for their preparation |
AU2001291815A AU2001291815B8 (en) | 2000-08-31 | 2001-08-31 | Percarboxylated polysaccharides, and a process for their preparation |
US10/376,369 US7683038B2 (en) | 2000-08-31 | 2003-02-28 | Percarboxylated polysaccharides, and a process for their preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD2000A000208 | 2000-08-31 | ||
IT2000PD000208A IT1317359B1 (en) | 2000-08-31 | 2000-08-31 | PERCARBOXYLATE POLYSACCHARIDES, SUCH AS HYALURONIC ACID, PROCESS FOR THEIR PREPARATION AND USE IN THE PHARMACEUTICAL FIELD AND |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/376,369 Continuation-In-Part US7683038B2 (en) | 2000-08-31 | 2003-02-28 | Percarboxylated polysaccharides, and a process for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002018448A2 true WO2002018448A2 (en) | 2002-03-07 |
WO2002018448A3 WO2002018448A3 (en) | 2002-05-16 |
Family
ID=11452056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/010062 WO2002018448A2 (en) | 2000-08-31 | 2001-08-31 | Percarboxylated polysaccharides, and a process for their preparation |
Country Status (7)
Country | Link |
---|---|
US (1) | US7683038B2 (en) |
EP (1) | EP1339753A2 (en) |
JP (1) | JP2004507586A (en) |
AU (2) | AU9181501A (en) |
CA (1) | CA2420618C (en) |
IT (1) | IT1317359B1 (en) |
WO (1) | WO2002018448A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003057203A2 (en) * | 2002-01-11 | 2003-07-17 | Fidia Farmaceutici S.P.A. | Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
WO2004060404A1 (en) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
FR2862979A1 (en) * | 2003-11-28 | 2005-06-03 | Centre Nat Rech Scient | BIOACTIVE BOXES FOR CELL CULTURES |
WO2007009728A2 (en) * | 2005-07-22 | 2007-01-25 | Fidia Advanced Biopolymers S.R.L. | Biomaterials based on carboxymethylcellulose salified with zinc associated with hyaluronic acid derivatives |
WO2007006403A3 (en) * | 2005-07-07 | 2007-04-26 | Fidia Advanced Polymers S R L | Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process |
JP2007524489A (en) * | 2004-02-27 | 2007-08-30 | フィディア アドヴァンスド バイオポリマーズ ソシエタ ア レスポンサビリタ リミタータ | Hyaluronic acid derivatives based on a three-dimensional matrix |
WO2008012365A2 (en) * | 2006-07-28 | 2008-01-31 | Eurand Pharmaceuticals Ltd. | Drug delivery system based on regioselectively amidated hyaluronic acid |
WO2009101518A3 (en) * | 2008-02-15 | 2010-10-14 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) | Gellan gum based hydrogels for regenerative medicine and tissue engineering applications, its system, and processing devices |
WO2011069474A2 (en) | 2009-12-11 | 2011-06-16 | Contipro C A.S. | Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof |
WO2011069475A2 (en) | 2009-12-11 | 2011-06-16 | Contipro C A.S. | A method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof |
WO2011119059A1 (en) * | 2010-03-26 | 2011-09-29 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec | Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
WO2011124381A1 (en) * | 2010-04-08 | 2011-10-13 | Merz Pharma Gmbh & Co. Kgaa | Fillers comprising gellan or pectin beads |
ITPD20100349A1 (en) * | 2010-11-19 | 2012-05-20 | Fidia Farmaceutici | PHARMACEUTICAL COMPOSITIONS WITH ANTIBACTERIAL AND CICATRIZING ACTIVITIES |
WO2012113529A1 (en) * | 2011-02-22 | 2012-08-30 | Merz Pharma Gmbh & Co. Kgaa | In situ formation of a filler |
WO2012146218A1 (en) * | 2011-04-24 | 2012-11-01 | Contipro Biotech S.R.O. | Amphoteric materials based on crosslinked hyaluronic acid, method of preparation thereof, materials containing entrapped active agents, method of preparation thereof, and use of said materials |
WO2013023793A3 (en) * | 2011-08-18 | 2013-05-10 | Albert-Ludwigs-Universität Freiburg | Matrices comprising a modified polysaccharide |
ITMI20120664A1 (en) * | 2012-04-20 | 2013-10-21 | Anika Therapeutics Srl | GELLANE BASED BIOMATERIALS FOR USE AS FILLER IN SURGERY |
WO2014082610A1 (en) * | 2012-11-27 | 2014-06-05 | Contipro Biotech S.R.O. | Endless fibres on the basis of hyaluronan selectively oxidized in the position 6 of the n-acetyl-d-glucosamine group, preparation and use thereof, threads, staples, yarns, fabrics made thereof and method for modifying the same |
EP2796100A1 (en) | 2013-04-23 | 2014-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gelling system for the removal of kidney stone fragments |
EP2796101A1 (en) | 2013-04-23 | 2014-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a cross-linked gel for encapsulating kidney stones and/or kidney stone fragments |
US9034624B2 (en) | 2009-06-16 | 2015-05-19 | Fidia Farmaceutici S.P.A. | Process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules, polymeric conjugates and relative uses thereof |
DE202013012275U1 (en) | 2013-04-23 | 2015-12-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a cross-linked gel for enclosing kidney stones and / or kidney stone fragments |
DE202013012287U1 (en) | 2013-04-23 | 2016-01-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gel-forming system for removing kidney stone fragments |
US9492586B2 (en) | 2012-02-28 | 2016-11-15 | Contipro Biotech S.R.O. | Derivatives of hyaluronic acid capable of forming hydrogels |
US9522966B2 (en) | 2012-08-08 | 2016-12-20 | Contipro Biotech S.R.O. | Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof |
US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
CN113509590A (en) * | 2021-06-07 | 2021-10-19 | 广东唯泰生物科技有限公司 | Wound dressing with exosome combined with hyaluronic acid and preparation method and application thereof |
US11407978B2 (en) | 2010-10-25 | 2022-08-09 | Albert-Ludwigs-Universität Freiburg | Extracellular matrices which can be used as scaffold for living cells |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPD20020271A1 (en) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | CHEMICAL-PHARMACEUTICAL COMPOUNDS CONSISTING OF TAXAN DERIVATIVES COVALENTLY LINKED TO HYALURONIC ACID OR ITS DERIVATIVES. |
EP1689787A2 (en) | 2003-11-28 | 2006-08-16 | Eastman Chemical Company | Cellulose interpolymers and method of oxidation |
ITPD20040245A1 (en) | 2004-10-08 | 2005-01-08 | Fidia Advanced Biopolymers Srl | BIOMATERIALS MADE UP OF HYALURONIC ACID, SULFATE AND GELL, USABLE IN THE PREVENTION OF SPINAL ADHESIONS |
ITPD20050242A1 (en) | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | BIOCONIUGATI ANTITUMORALI OF HYALURONIC ACID OR ITS DERIVATIVES, OBTAINABLE FOR DIRECT OR INDIRECT CHEMICAL CONJUGATION, AND THEIR USE IN PHARMACEUTICAL FIELD |
CN100348621C (en) * | 2005-12-02 | 2007-11-14 | 凌沛学 | Bismuth hyalurate and its preparation method and uses |
ITMI20071267A1 (en) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | USE OF CONJUGATES OF HYALURONIC ACID IN LOCAL TREATMENT OF HYPERPROLIFERATIVE SKIN DISEASES |
ITMI20071724A1 (en) | 2007-09-05 | 2009-03-06 | Fidia Farmaceutici | ANTIVIRAL TOPIC FORMULATIONS IN THE FORM OF BIOADESIVE GEL |
CN104888264B (en) | 2008-01-14 | 2018-01-09 | 北京环球利康科技有限公司 | Biocompatible hemostatic, prevent adhesion, the modified starch material of promoting healing, surgery closing |
US8343942B2 (en) | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
JP5758797B2 (en) * | 2008-04-04 | 2015-08-05 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | Alkylated semi-synthetic glycosaminoglycan ethers and methods for their production and use |
US20160145567A1 (en) * | 2010-05-27 | 2016-05-26 | Corning Incorporated | Cell culture article and methods thereof |
ES2385239B1 (en) | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | USE OF RECOMBINANT COLAGENASE G, RECOMBINANT H COLAGENASE AND RECOMBINING PZ-PEPTIDASE FOR THE TREATMENT OF DISEASES THAT ARE CURRENT WITH ALTERATIONS OF THE COLLAGEN. |
EP2688402B1 (en) | 2011-03-23 | 2018-10-24 | University of Utah Research Foundation | Means for treating or preventing urological inflammation |
WO2013188534A1 (en) * | 2012-06-12 | 2013-12-19 | Rutgers, The State University Of New Jersey | Biomaterials for the prevention of post-operative adhesions |
ITMI20131971A1 (en) * | 2013-11-26 | 2015-05-27 | Fidia Farmaceutici | PHARMACEUTICAL COMPOSITIONS WITH MOISTURIZING AND LUBRICATING ACTIVITY |
CN107073031B (en) | 2014-06-15 | 2021-08-24 | 耶达研究及发展有限公司 | Surface treatment with water-soluble polymers and lipids/liposomes |
NZ747413A (en) | 2016-04-27 | 2020-09-25 | Anika Therapeutics Inc | Compositions for use in treating tendon degeneration |
JP6139754B1 (en) * | 2016-06-17 | 2017-05-31 | 株式会社ユーグレナ | Cell growth promoter |
JP2021510574A (en) | 2018-01-10 | 2021-04-30 | ザ プロボスト フェローズ スカラーズ アンド アザー メンバーズ オブ ボード オブ トリニティ カレッジ ダブリン | Systems and methods for closing pathways within an organization |
WO2020144372A1 (en) | 2019-01-10 | 2020-07-16 | The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin | Composite viscoelastic hydrogel, and uses thereof for sealing a channel in tissue |
IT201900006250A1 (en) | 2019-04-23 | 2020-10-23 | Fidia Farm Spa | MEDICATION FOR THE TREATMENT OF THE INJURED SKIN |
WO2020240034A1 (en) | 2019-05-31 | 2020-12-03 | University College Dublin | Hyaluronic acid-based hybrid hydrogel |
IT202100032111A1 (en) * | 2021-12-22 | 2023-06-22 | Fidia Farm Spa | NEW BIOCOMPATIBLE SUBSTITUTES OF THE VITREOUS HUMOR |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038484A1 (en) * | 1995-06-02 | 1996-12-05 | Coöperatieve Verkoop- En Productievereniging Van Aardappelmeel En Derivaten Avebe B.A. | Oxidized polymeric carbohydrate ethers for use as sequestering agent, and methods for the preparation thereof |
WO1998045335A1 (en) * | 1997-04-04 | 1998-10-15 | Fidia Advanced Biopolymers, S.R.L. | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation |
WO2000001733A1 (en) * | 1998-07-06 | 2000-01-13 | Fidia Advanced Biopolymers S.R.L. | Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US4746504A (en) * | 1986-03-14 | 1988-05-24 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
IT1198449B (en) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
JPH10204102A (en) * | 1997-01-27 | 1998-08-04 | Mitsubishi Gas Chem Co Inc | Production of water-soluble tricarboxy polysaccharide |
US20030073663A1 (en) * | 1997-06-25 | 2003-04-17 | David M Wiseman | Bioabsorbable medical devices from oxidized polysaccharides |
US6586588B1 (en) * | 1999-08-17 | 2003-07-01 | National Starch And Chemical Investment Holding Corporation | Polysaccharide aldehydes prepared by oxidation method and used as strength additives in papermaking |
-
2000
- 2000-08-31 IT IT2000PD000208A patent/IT1317359B1/en active
-
2001
- 2001-08-31 EP EP01971988A patent/EP1339753A2/en not_active Withdrawn
- 2001-08-31 CA CA2420618A patent/CA2420618C/en not_active Expired - Lifetime
- 2001-08-31 AU AU9181501A patent/AU9181501A/en active Pending
- 2001-08-31 WO PCT/EP2001/010062 patent/WO2002018448A2/en active Application Filing
- 2001-08-31 AU AU2001291815A patent/AU2001291815B8/en not_active Ceased
- 2001-08-31 JP JP2002523962A patent/JP2004507586A/en active Pending
-
2003
- 2003-02-28 US US10/376,369 patent/US7683038B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038484A1 (en) * | 1995-06-02 | 1996-12-05 | Coöperatieve Verkoop- En Productievereniging Van Aardappelmeel En Derivaten Avebe B.A. | Oxidized polymeric carbohydrate ethers for use as sequestering agent, and methods for the preparation thereof |
WO1998045335A1 (en) * | 1997-04-04 | 1998-10-15 | Fidia Advanced Biopolymers, S.R.L. | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation |
WO2000001733A1 (en) * | 1998-07-06 | 2000-01-13 | Fidia Advanced Biopolymers S.R.L. | Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
Non-Patent Citations (2)
Title |
---|
DATABASE CHEMICAL ABSTRACTS [Online] Chemical Abstracts Service, Columbus OH/USA; Accession no. 135:346080, 2000 XP002189577 & R. LANZETTA ET AL.: "Use of Carbohydrates in Tanning Technology" CUOIO, PELLI, MATERIE CONCIANTI, vol. 76, no. 6, 2000, pages 325-334, * |
JIANG B ET AL: "Study on TEMPO-mediated selective oxidation of hyaluronan and the effects of salt on the reaction kinetics" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 327, no. 4, 7 August 2000 (2000-08-07), pages 455-461, XP004213357 ISSN: 0008-6215 cited in the application * |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003201618B2 (en) * | 2002-01-11 | 2008-11-06 | Deutsches Krebsforschungszentrum (Dkfz) | Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
WO2003057203A3 (en) * | 2002-01-11 | 2003-12-31 | Fidia Farmaceutici | Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
US7838510B2 (en) | 2002-01-11 | 2010-11-23 | Fidia Farmaceutici S.P.A. | Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors |
WO2003057203A2 (en) * | 2002-01-11 | 2003-07-17 | Fidia Farmaceutici S.P.A. | Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
WO2004060404A1 (en) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
WO2005054424A2 (en) * | 2003-11-28 | 2005-06-16 | Centre National De La Recherche Scientifique | Bioactive boxes for cellular cultures |
WO2005054424A3 (en) * | 2003-11-28 | 2005-08-18 | Centre Nat Rech Scient | Bioactive boxes for cellular cultures |
FR2862979A1 (en) * | 2003-11-28 | 2005-06-03 | Centre Nat Rech Scient | BIOACTIVE BOXES FOR CELL CULTURES |
JP2007524489A (en) * | 2004-02-27 | 2007-08-30 | フィディア アドヴァンスド バイオポリマーズ ソシエタ ア レスポンサビリタ リミタータ | Hyaluronic acid derivatives based on a three-dimensional matrix |
WO2007006403A3 (en) * | 2005-07-07 | 2007-04-26 | Fidia Advanced Polymers S R L | Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process |
WO2007009728A2 (en) * | 2005-07-22 | 2007-01-25 | Fidia Advanced Biopolymers S.R.L. | Biomaterials based on carboxymethylcellulose salified with zinc associated with hyaluronic acid derivatives |
WO2007009728A3 (en) * | 2005-07-22 | 2007-06-07 | Fidia Advanced Biopolymers Srl | Biomaterials based on carboxymethylcellulose salified with zinc associated with hyaluronic acid derivatives |
WO2008012365A2 (en) * | 2006-07-28 | 2008-01-31 | Eurand Pharmaceuticals Ltd. | Drug delivery system based on regioselectively amidated hyaluronic acid |
WO2008012365A3 (en) * | 2006-07-28 | 2008-05-22 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
WO2009101518A3 (en) * | 2008-02-15 | 2010-10-14 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) | Gellan gum based hydrogels for regenerative medicine and tissue engineering applications, its system, and processing devices |
US9034624B2 (en) | 2009-06-16 | 2015-05-19 | Fidia Farmaceutici S.P.A. | Process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules, polymeric conjugates and relative uses thereof |
WO2011069475A2 (en) | 2009-12-11 | 2011-06-16 | Contipro C A.S. | A method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof |
US9434791B2 (en) | 2009-12-11 | 2016-09-06 | Contipro Pharma A.S. | Method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof |
WO2011069474A2 (en) | 2009-12-11 | 2011-06-16 | Contipro C A.S. | Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof |
US9403918B2 (en) | 2009-12-11 | 2016-08-02 | Contipro Pharma A.S. | Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof |
US9012415B2 (en) | 2010-03-26 | 2015-04-21 | Stemmatters, Biotecnologia E Medicina Regenerativa S.A. | Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
WO2011119059A1 (en) * | 2010-03-26 | 2011-09-29 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec | Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
WO2011124381A1 (en) * | 2010-04-08 | 2011-10-13 | Merz Pharma Gmbh & Co. Kgaa | Fillers comprising gellan or pectin beads |
US11407978B2 (en) | 2010-10-25 | 2022-08-09 | Albert-Ludwigs-Universität Freiburg | Extracellular matrices which can be used as scaffold for living cells |
ITPD20100349A1 (en) * | 2010-11-19 | 2012-05-20 | Fidia Farmaceutici | PHARMACEUTICAL COMPOSITIONS WITH ANTIBACTERIAL AND CICATRIZING ACTIVITIES |
WO2012066447A1 (en) * | 2010-11-19 | 2012-05-24 | Fidia Farmaceutici S.P.A. | Compositions with antibacterial and wound healing activity |
US9265793B2 (en) | 2010-11-19 | 2016-02-23 | Fidia Farmaceutici S.P.A | Compositions with antibacterial and wound healing activity |
WO2012113529A1 (en) * | 2011-02-22 | 2012-08-30 | Merz Pharma Gmbh & Co. Kgaa | In situ formation of a filler |
WO2012146218A1 (en) * | 2011-04-24 | 2012-11-01 | Contipro Biotech S.R.O. | Amphoteric materials based on crosslinked hyaluronic acid, method of preparation thereof, materials containing entrapped active agents, method of preparation thereof, and use of said materials |
US12030963B2 (en) | 2011-08-18 | 2024-07-09 | Maptech Holdings Ug | Matrices comprising a modified polysaccharide |
US10968285B2 (en) | 2011-08-18 | 2021-04-06 | Albert-Ludwigs Universität Freiburg | Matrices comprising a modified polysaccharide |
WO2013023793A3 (en) * | 2011-08-18 | 2013-05-10 | Albert-Ludwigs-Universität Freiburg | Matrices comprising a modified polysaccharide |
US9492586B2 (en) | 2012-02-28 | 2016-11-15 | Contipro Biotech S.R.O. | Derivatives of hyaluronic acid capable of forming hydrogels |
ITMI20120664A1 (en) * | 2012-04-20 | 2013-10-21 | Anika Therapeutics Srl | GELLANE BASED BIOMATERIALS FOR USE AS FILLER IN SURGERY |
US9522966B2 (en) | 2012-08-08 | 2016-12-20 | Contipro Biotech S.R.O. | Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof |
US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
WO2014082610A1 (en) * | 2012-11-27 | 2014-06-05 | Contipro Biotech S.R.O. | Endless fibres on the basis of hyaluronan selectively oxidized in the position 6 of the n-acetyl-d-glucosamine group, preparation and use thereof, threads, staples, yarns, fabrics made thereof and method for modifying the same |
EP2796101A1 (en) | 2013-04-23 | 2014-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a cross-linked gel for encapsulating kidney stones and/or kidney stone fragments |
DE202013012287U1 (en) | 2013-04-23 | 2016-01-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gel-forming system for removing kidney stone fragments |
US9925311B2 (en) | 2013-04-23 | 2018-03-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a crosslinked gel for surrounding urinary calculi and/or fragments thereof |
WO2014173468A1 (en) | 2013-04-23 | 2014-10-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a crosslinked gel for surrounding urinary calculi and/or fragments thereof |
US10232079B2 (en) | 2013-04-23 | 2019-03-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gel-forming system for removing urinary calculi and fragments thereof |
WO2014173467A1 (en) | 2013-04-23 | 2014-10-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gel-forming system for removing urinary calculi and fragments thereof |
DE202013012275U1 (en) | 2013-04-23 | 2015-12-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit for producing a cross-linked gel for enclosing kidney stones and / or kidney stone fragments |
EP2796100A1 (en) | 2013-04-23 | 2014-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gelling system for the removal of kidney stone fragments |
US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
CN113509590A (en) * | 2021-06-07 | 2021-10-19 | 广东唯泰生物科技有限公司 | Wound dressing with exosome combined with hyaluronic acid and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20030181689A1 (en) | 2003-09-25 |
EP1339753A2 (en) | 2003-09-03 |
ITPD20000208A1 (en) | 2002-03-03 |
US7683038B2 (en) | 2010-03-23 |
AU2001291815B8 (en) | 2006-03-30 |
ITPD20000208A0 (en) | 2000-08-31 |
CA2420618A1 (en) | 2002-03-07 |
IT1317359B1 (en) | 2003-06-16 |
CA2420618C (en) | 2012-01-03 |
AU2001291815B2 (en) | 2006-03-02 |
WO2002018448A3 (en) | 2002-05-16 |
JP2004507586A (en) | 2004-03-11 |
AU9181501A (en) | 2002-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2420618C (en) | Percarboxylated polysaccharides, and a process for their preparation | |
AU2001291815A1 (en) | Percarboxylated polysaccharides, and a process for their preparation | |
EP1313772B1 (en) | New cross-linked derivatives of hyaluronic acid | |
JP4791921B2 (en) | Hyaluronic acid amides and their derivatives, and methods for their production | |
AU2002213870A1 (en) | New cross-linked derivatives of hyaluronic acid | |
AU2007296939B2 (en) | Hyaluronic acid derivatives obtained via "click chemistry" crosslinking | |
JP4278716B2 (en) | N-sulfated hyaluronic acid compound, derivative thereof and production method | |
RU2230073C2 (en) | Method for cross-linking carboxylated polysaccharides | |
JP2855307B2 (en) | Photoreactive glycosaminoglycans, cross-linked glycosaminoglycans and methods for producing them | |
CZ296842B6 (en) | Cross-linked hyaluronic acids | |
JP2001510713A (en) | Use of a hyaluronic acid derivative in the manufacture of a biocompatible material having physical hemostatic and embolic activity and prophylactic activity against adhesion formation after anastomosis | |
CA3135919A1 (en) | Crosslinked polymer of functionalized hyaluronic acid and its use in the treatment of inflammatory states | |
WO2018079812A1 (en) | Gel composition and method for producing same | |
ITPD980022A1 (en) | N-SULPHATED COMPOUNDS OF HYALURONIC ACID AND ITS DERIVATIVES WITH ANTI-AGING AND ANTI-THROMBOTIC ACTIVITY AND PROCESS FOR PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2420618 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002523962 Country of ref document: JP Ref document number: 10376369 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2001971988 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001971988 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001291815 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001971988 Country of ref document: EP |